Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
May 08, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
May 07, 2024 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024...
April 30, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
April 24, 2024 16:01 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
April 17, 2024 20:46 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Prices Public Offering of Common Stock

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
April 16, 2024 16:06 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
April 16, 2024 07:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change...
March 19, 2024 08:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
March 06, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...